Navigating the challenges of colorectal cancer screening

Exact Sciences is uniquely positioned to support your efforts with a CRC screening solution backed by an understanding of health systems' needs and priorities.
Physician roundtable meeting.

Connect with us

Explore how we can support your health system’s efforts to improve CRC screening rates.
Closing the colorectal cancer (CRC) screening gap is critical to improve quality measures, provide better outcomes, and enhance the patient experience. With many health systems facing challenges meeting CRC screening goals, it's time to consider a company with a strong history of collaborating with health systems to develop multidisciplinary, standardized, and scalable CRC screening solutions.
CRC screening rates by demographic indicators.

An estimated 60 million Americans are due for CRC screening3

CRC remains “the most preventable, yet least prevented, cancer.”4 National CRC screening rates remain well below established goals.1,2

Real-world experience

See how other health systems have successfully collaborated with Exact Sciences to improve cancer screening.
CRC treatment costs increase with each stage of diagnosis5
Costs per Medicare patient increases >3x from Stage I to Stage IV

Loading component...

Cologuard first. Colonoscopy as needed.

For 10 years, the Cologuard test has set the standard for stool DNA-based testing in average-risk individuals aged 45 or older.16

Visit the healthcare provider page to learn more about the test.

For patients who remain unscreened—the SimpleScreen CRC test

An FDA-approved screening option for average-risk patients 45+.9 CRC blood tests are recommended by the American Cancer Society (ACS) for those who will not complete a preferred screening test.6 SimpleScreen CRC was developed and manufactured by Freenome, LLC.

Visit the healthcare provider page to learn more about the test

Solutions from a partner that understands your business

There's more to CRC screening than just a test result. Exact Sciences offers:

Optimized workflows

Optimizing workflows to help achieve CRC screening goals and improve quality measure scores

Digital health infrastructure

Promoting efficiency by maximizing the capabilities of your digital health infrastructure

3 years of credits

The Cologuard Plus test satisfies 3 years of Healthcare Effectiveness Data and Information Set (HEDIS®) credits10,17,18,||¶
Connect with us
Explore how we can support your health system's goals for improving CRC screening rates.

Important Information about the Cologuard products

The Cologuard test and Cologuard Plus test are indicated to screen adults, 45 years or older, who are at average risk for CRC. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. Not a replacement for colonoscopy in high-risk individuals. False positive and negative results may occur. Rx only. See more information about Cologuard and SimpleScreen CRC at Cologuard.com/risk- information.

Important Information about the SimpleScreen CRC test

SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.

Precaution: Based on data from clinical studies, SimpleScreen CRC has limited detection (57%) of Stage I colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted). One out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a screening colonoscopy. Rx only. IVD. See more information about Cologuard and SimpleScreen CRC at Cologuard.com/risk-information.

Developed and manufactured by Freenome, LLC. Distributed by Abbott.